The Shenzen-based sequencing technology company plans to use the money to boost its R&D for multiomics technologies and fuel ...

The patents at issue involve methods involving the bisulfite conversion of cell-free DNA from a blood-derived sample, ...

NEW YORK – AstraZeneca said on Friday the Phase III trial of its oral selective estrogen receptor degrader Etcamah (camizestrant) in frontline estrogen receptor (ER)-positive, HER2-negative advanced ...

BBB National Programs’ National Advertising Division asked controversial startup Nucleus Genomics to stop using certain ...

New products for the week of Sept. 7, 2026: Google, BGI Genomics, and Helix.

Moonwalk Biosciences said it will use the funds to advance its lead candidate for obesity, MW101, into clinical testing by late 2027.

NEW YORK – Tempus AI said on Friday that it is building a database containing 100,000 whole genomes linked to longitudinal clinical information over the next several years to help advance artificial ...

BGI Genomics has launched the Family Heritage genomic assay, a whole-genome test that combines short- and long-read sequencing for family members.

Google DeepMind has launched AlphaGenome Atlas ...

NEW YORK – Clinical labs are raising concerns over a proposed rule by the US Centers for Medicare and Medicaid Services (CMS) that would move reimbursement for algorithm-only lab testing off the ...

The investment bank gave Grail a price target of $105 and Caris, Tempus, and Twist price targets of $28, $70, and $144, respectively.